Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Clinical Study to Investigate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of BTK Inhibitor BGB-3111 in Chinese Patients With B-cell Lymphoma

Next Previous
Trial Profile

A Phase I Clinical Study to Investigate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of BTK Inhibitor BGB-3111 in Chinese Patients With B-cell Lymphoma

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 30 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zanubrutinib (Primary)
  • Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors BeiGene

Most Recent Events

  • 15 Jun 2023 Results of pooled analysis from (BGB-3111-AU-003, BGB-3111-215, BGB-3111-216, BGB-3111-1002,BGB-3111-GA-101) assessing comparative summary of safety and efficacy data between the QD and BID regimens in patients with various B-cell malignancies presented at the 28th Congress of the European Haematology Association
  • 28 Jul 2022 Results of a pooled post-hoc analysis assessing long-term follow-up outcomes of zanubrutinib in various lines of therapy in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma from following clinical studies: NCT03189524, NCT02343120 and NCT03206918 published in the Advances in Therapy
  • 01 Jul 2022 Results assessing safety and preliminary anti-tumour activity, published in the British Journal of Haematology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top